Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Thermo,
I've liked your projections and the details on Reddit from another poster.
* https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173887120
* https://www.reddit.com/r/OTLK_Investors/comments/18sfaok/otlkbuyout_my_view_of_profits_at_december_22_2023
I'm a bit cagey when it comes to revenue projections, payors, price point, etc. On my side, I see a significant upside given the current MC at less than $200M and I'm good with that. Even with Europe only, the MC should improve on launch/revenue/country by country, so I'm staying invested. It may take 'a while', which in the biotech world is longer than in other industries :)
Then there is the possibility of a buy out. That would not surprise me a bit.
I'm looking forward to read more of your insights. You are one of my favorite posters on IHub.
Have a great day!
Best of luck with your investments!
Hi Zadie420,
After the CRL from the FDA last year, OTLK passed an SPA (semi binding agreement) with the FDA around Norse 8.
"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)"
OTLK is planning on recruiting about 400 patients from 60 sites (that's why I'm tracking the site numbers) in order to achieve the powering of the study.
IF (a big IF, but really, that's what I'm expecting) Norse 8 is successful, OTLK will submit Norse 8 as the basis for approval of ONS-5010 in the US. This submittal has been and is still planned for the end of the year. (There is planning, then there is reality). Then it's up to the FDA to finally deliver an approval or reject it.
Now, OTLK has been accepted in Europe on the basis of previous trials (which to me should have been sufficient for the FDA as well. I think the FDA is not quite straight with OTLK, but that's my own take), and the 3 months Norse 8 should confirm that (again, my opinion).
So I'm tracking a couple of things on the US side:
* The number of recruiting sites: 59 for now, they may not need 60, but they planned on it, so maybe one more
* The change in status from Recruiting to another status, like "Active, not recruiting" which might indicate all 400 patients (or a bit more) have been enrolled.
On the status change milestone, you know that the trial has 3 more months to unfold, then data collection, etc., leading to submittal.
Best of luck with your investments!
1 more site, so 59 sites now
* Oceanside, New York, United States, 11572
See: https://clinicaltrials.gov/study/NCT06190093?term=norse%20eight&checkSpell=false&rank=1#contacts-and-locations
They had planned for 60, again, not sure they'll need all, but that's 1 to go if so.
Minor good non-news: Even though the update is dated 5/30 or 6/3 depending on how you read it, the estimate dates remain the same:
* Study Start: January 24, 2024
* Primary Completion: September 2024 [Anticipated]
* Study Completion: October 2024 [Anticipated]
The current list of recruiting sites:
Arcadia, California, United States, 91006
Bakersfield, California, United States, 93309
Beverly Hills, California, United States, 90210
Huntington Beach, California, United States, 92647
Laguna Hills, California, United States, 92653
Long Beach, California, United States, 90807
Modesto, California, United States, 95356
Pasadena, California, United States, 91107
Poway, California, United States, 92064
Sacramento, California, United States, 95841
Colorado Springs, Colorado, United States, 80909
Lakewood, Colorado, United States, 80228
Waterford, Connecticut, United States, 06385
Coral Springs, Florida, United States, 33067
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32216
Orlando, Florida, United States, 32806
Stuart, Florida, United States, 34994
Oak Forest, Illinois, United States, 60452
Oak Park, Illinois, United States, 03440
Lenexa, Kansas, United States, 66215
Lexington, Kentucky, United States, 40509
Hagerstown, Maryland, United States, 21740
Edina, Minnesota, United States, 55435
Saint Louis Park, Minnesota, United States, 55416
Jackson, Mississippi, United States, 39202
Teaneck, New Jersey, United States, 07666
Albuquerque, New Mexico, United States, 87109
Liverpool, New York, United States, 13088
Oceanside, New York, United States, 11572
Rochester, New York, United States, 14620
Westbury, New York, United States, 11590
Asheville, North Carolina, United States, 28803
Hickory, North Carolina, United States, 28602
Wake Forest, North Carolina, United States, 27587
Winston-Salem, North Carolina, United States, 27103
Edmond, Oklahoma, United States, 73013
Charleston, South Carolina, United States, 29414
Florence, South Carolina, United States, 29501
Ladson, South Carolina, United States, 29456
West Columbia, South Carolina, United States, 29169
Rapid City, South Dakota, United States, 57701
Germantown, Tennessee, United States, 38138
Abilene, Texas, United States, 79606
Arlington, Texas, United States, 76012
Austin, Texas, United States, 78705
Beaumont, Texas, United States, 77707
Bellaire, Texas, United States, 77401
Dallas, Texas, United States, 75231
Round Rock, Texas, United States, 78681
San Antonio, Texas, United States, 78240
San Antonio, Texas, United States, 78251
The Woodlands, Texas, United States, 77384
Willow Park, Texas, United States, 79606
Salt Lake City, Utah, United States, 84107
Fairfax, Virginia, United States, 22031
Lynchburg, Virginia, United States, 24502
Bellevue, Washington, United States, 98004
Silverdale, Washington, United States, 98383
Best of luck with your investments!
BTIG: $50 PT post European approval
Thanks Thermo
Best of luck with your investments!
On a related note, Market Beat has a PT of $46 i.e. an upside of 485%
https://www.marketbeat.com/stocks/nasdaq/otlk/
I'm curious to see if analysts revise their target after yesterday's announcement.
Best of luck with your investments.
Hi Zadie420
1. The FDA will rely on Norse 8 for approval. OTLK hopes/plans on submital to the FDA in Dec 2024, the FDA then will finalize its decision. I don't know how fast that will be.
2. In terms of revenue, some folks have done detailed projections, such as:
> https://www.reddit.com/media?url=https%3A%2F%2Fpreview.redd.it%2Fotlk-buyout-my-view-of-profits-at-december-22-2023-form-10-k-v0-tknunuoqdx8c1.png%3Fwidth%3D1487%26format%3Dpng%26auto%3Dwebp%26s%3D75d3459965d1c999d07ba9517dd84c1de32b00e7
to estimate a possible buy out at over $5B
or another view from thermo (one of my favorite posters):
> https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173887120
with peak sales at over $500M and market cap at about $2B
anyways, that would drive the PPS significantly up.
Best of luck with your investments!
Hello Thermo,
Your hunch on European approval was spot on.
What do you make of today's PPS action: fairly average volume, going down 12%, recovering towards the end of the day, but with no significant gain overall. The difference between Friday and today is the approval, and yet, not significant bump in the PPS.
Any insight as to what may be happening? as to what will unfold PPS-wise over the course of the next few weeks?
Thanks Thermo!
Best of luck with your investments!
I bought more with the PPS dropping on good news.
The market cap is around $180M, and with approval, the PPS goes down? Yep, I did buy more.
Also, it bodes well for US approval post Norse 8.
Best of luck with your investments!
10 years exclusivity, 27 countries.
European Marketing Authorization for LYTENAVA™ granted!
https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-receives-european-commission-marketing
Best of luck with your investments!
Positive or negative, the EU is supposed to give its verdict this week for ONS-5010.
Let's see if they keep to their timetable. I'm cautiously optimistic.
Best of luck with your investments!
European news within a couple of weeks?
That's what the May 14th PR hinted at:
As previously announced, Outlook Therapeutics received a CHMP positive opinion on March 22, 2024 concerning an application for grant of marketing authorization for ONS-5010/LYTENAVA™ in the EU. The European Commission is expected to make a decision within approximately 67 days following the CHMP opinion. The decision will apply automatically in all 27 EU Member States, and, within 30 days, also to Iceland, Norway and Liechtenstein.
May 13 PR: MHRA Submission / Under IRP
https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-announces-uk-submission-marketing
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
May 13, 2024
UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma)
ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and Europe, today announced the submission of its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).
The submission was completed under the new International Recognition Procedure (IRP), which allows the MHRA to rely on a positive opinion by the European Medicines Agency’s CHMP concerning an application for grant of marketing authorization for the same product in the EU. The IRP is available for new UK MAAs of a medicinal product (having the same qualitative and quantitative composition, and the same pharmaceutical form) that has previously been authorized by a Reference Regulator (RR). In this case this is the EMA.
“The submission of our MAA to the MHRA is another step closer to the possibility of offering clinicians and their patients in the UK market the only on-label, ophthalmic bevacizumab to treat wet AMD,” said Russell Trenary, President and CEO of Outlook Therapeutics. “On the heels of the recent positive opinion by the CHMP in the EU, we continue to make noteworthy progress toward the potential authorization of ONS-5010/LYTENAVA™ in the UK.”
The MAA submission is supported by results from Outlook Therapeutics’ wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials – NORSE ONE, NORSE TWO and NORSE THREE.
As previously announced, Outlook Therapeutics received a CHMP positive opinion on March 22, 2024 concerning an application for grant of marketing authorization for ONS-5010/LYTENAVA™ in the EU. The European Commission is expected to make a decision within approximately 67 days following the CHMP opinion. The decision will apply automatically in all 27 EU Member States, and, within 30 days, also to Iceland, Norway and Liechtenstein.
2 more sites, so now 58
* Laguna Hills, California, United States, 92653
* Hagerstown, Maryland, United States, 21740
They may go for the 60 planned or not, depending of the recruitment progress. The primary completion and study completion anticipated dates remain the same.
And end of May (European decision) is tip-toeing forward.
Best of luck with your investments!
OS: placebo: 7.7 months, poly-ICLC: 52.5 months
https://www.nature.com/articles/s41467-024-48073-y
If there is one simple stat to remember from the Ph II / DCVax-L + Poly-ICLC, that would be it. In Nature!
Best of luck to Patients, NWBO, and Longs!
May! Here is to good news before the end of the month.
The March 22nd PR stated that:
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days
Me too, been 'Long' over ten years, and definitely not selling shares now that we are this close. Once the submittal was official, there was no way I was going to sell a single share. Confidently hopeful.
Best of luck with your investments!
1 more site -> 56 as of April 24th
-> Lenexa, Kansas, United States, 66215
I also pay attention to the completion dates. They have not moved since the first version on clinical trials. They are:
* Primary Completion: September 2024 [Anticipated]
* Study Completion: October 2024 [Anticipated]
with the resubmittal planned by the end of the year. Even if it moved a bit, say January, that's in the ballpark.
At this stage, OTLK must be seeing the current enrollment and continue to plan accordingly. The completion dates can be updated with each new revision. And they keep being the same.
I'm not sure that all 60 planned sites are necessary for the enrollment. It's now 56 recruiting sites out of 60 planned.
And then, there is the end of May European decision.
Best of luck with your investments!
2 more sites -> 55 as of April 16th
Arcadia, California, United States, 91006
Pasadena, California, United States, 91107
Close to the 60 planned sites. Around end of April for the remaining sites sounds doable. If they need them.
Best of luck with your investments!
Thanks someconcerns
That follows what they announced on March 18:
As previously disclosed, Outlook Therapeutics also entered into a securities purchase agreement with Syntone Ventures, another existing stockholder, to purchase $5 million in shares of common stock and warrants on the same terms as the private placement. The closing of the Syntone investment remains subject to receipt of regulatory approvals and other customary closing conditions.
Institutional Trading
BlackRock Inc. raised its stake in shares of Outlook Therapeutics by 14.2% during the second quarter. BlackRock Inc. now owns 9,215,800 shares of the company's stock valued at $16,035,000 after acquiring an additional 1,148,372 shares during the last quarter.
Vanguard Group Inc. raised its stake in shares of Outlook Therapeutics by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 6,560,400 shares of the company's stock valued at $2,585,000 after acquiring an additional 277,326 shares during the last quarter.
State Street Corp raised its stake in shares of Outlook Therapeutics by 36.2% during the second quarter. State Street Corp now owns 2,751,977 shares of the company's stock valued at $4,788,000 after acquiring an additional 731,925 shares during the last quarter.
Finally, Geode Capital Management LLC raised its stake in shares of Outlook Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 2,720,795 shares of the company's stock valued at $4,734,000 after acquiring an additional 183,120 shares during the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.
$46.43 Consensus PT from Analysts
https://www.marketbeat.com/instant-alerts/nasdaq-otlk-consensus-analyst-rating-2024-04-13/
A bit similar to the article from 3 weeks ago
https://www.marketbeat.com/instant-alerts/nasdaq-otlk-consensus-analyst-rating-2024-04-13/
Probably generated from data from back then, but still interesting.
Best of luck with your investments.
53 sites as of April 10th
Added sites:
Long Beach, California, United States, 90807
Lexington, Kentucky, United States, 40509
7 to go if they want to reach the full 60, which may or may not be necessary to enroll the planned 400 patients.
Most likely starting in August, I'll be checking the 'Recruiting' status. That should give us a great clue.
Best of luck with your investments!
Update: 51 sites recruiting / 60 planned as of yesterday
Bakersfield, California, United States, 93309
Beverly Hills, California, United States, 90210
Huntington Beach, California, United States, 92647
Modesto, California, United States, 95356
Poway, California, United States, 92064
Sacramento, California, United States, 95841
Colorado Springs, Colorado, United States, 80909
Lakewood, Colorado, United States, 80228
Waterford, Connecticut, United States, 06385
Coral Springs, Florida, United States, 33067
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32216
Orlando, Florida, United States, 32806
Stuart, Florida, United States, 34994
Oak Forest, Illinois, United States, 60452
Oak Park, Illinois, United States, 03440
Edina, Minnesota, United States, 55435
Saint Louis Park, Minnesota, United States, 55416
Jackson, Mississippi, United States, 39202
Teaneck, New Jersey, United States, 07666
Albuquerque, New Mexico, United States, 87109
Liverpool, New York, United States, 13088
Rochester, New York, United States, 14620
Westbury, New York, United States, 11590
Asheville, North Carolina, United States, 28803
Hickory, North Carolina, United States, 28602
Wake Forest, North Carolina, United States, 27587
Winston-Salem, North Carolina, United States, 27103
Edmond, Oklahoma, United States, 73013
Charleston, South Carolina, United States, 29414
Florence, South Carolina, United States, 29501
Ladson, South Carolina, United States, 29456
West Columbia, South Carolina, United States, 29169
Rapid City, South Dakota, United States, 57701
Germantown, Tennessee, United States, 38138
Abilene, Texas, United States, 79606
Arlington, Texas, United States, 76012
Austin, Texas, United States, 78705
Beaumont, Texas, United States, 77707
Bellaire, Texas, United States, 77401
Best of luck with your investments!
45 out of 60 sites are recruiting
I keep an eye on the number of recruiting sites. The March presentation, slide 17, shows a planned number of recruiting sites at 60.
https://ir.outlooktherapeutics.com/static-files/cfa0c7ae-7b5e-4500-b21f-cc1a2243d2aa
As of the latest clinical trial update, March 29th, the number of sites was 45. 15 to go, or at the same cadence, about another month (45 sites in the first three months).
With the March presentation, the FDA timeline is in keeping with the previous PRs and presentations. And OTLK has a history of following timelines. So even if it does not unfold exactly as planned, I expect the timeline to be pretty close, maybe a month off but not 4 months for instance.
The rest of the presentation looks similar to previous ones, with more of a focus on European activities and money raises.
Best of luck with your investments!
Overall Planned MIlestones
Main point for the FDA resubmittal:
* Q3 full enrollment -> Q4 resubmittal
From the March presentation:
https://ir.outlooktherapeutics.com/static-files/cfa0c7ae-7b5e-4500-b21f-cc1a2243d2aa
Best of luck with your investments
Seeking Alpha: Positive Article
https://seekingalpha.com/article/4681360-outlook-therapeutics-de-risked-regulatory-tracks-are-lining-up-for-possible-ons-5010-approval
The article recaps most of the latest developments fairly well. I copied the conclusion below:
Outlook Therapeutics has done well to advance its lead program in its pipeline, which is the use of ONS-5010 for the treatment of patients with Wet age-related macular degeneration [Wet-AMD]. It has already de-risked this asset on two fronts, which would be on possible U.S. and European approvals. With respect to possible U.S. approval of this drug, it is all going to depend upon what the final results from the phase 3 NORSE EIGHT study are going to be. That is, upon whether or not the primary endpoint of BCVA is going to be met with statistical significance in this trial.
However, I believe that an even better opportunity lies with respect to European approval. Why is that? That's because the EC didn't require another study for potential ONS-5010 approval. Not only that, but the CHMP has already pretty much given a positive opinion on it. This doesn't mean that European approval is guaranteed to happen, but it greatly increases the odds of it. With several catalysts on the way in 2024, plus continued regulatory advancement of ONS-5010 on two fronts, I believe that investors could benefit with any potential gains.
5 more sites added on 3/27/2024, now 44 sites
Bakersfield, California, United States, 93309
Beverly Hills, California, United States, 90210
Huntington Beach, California, United States, 92647
Modesto, California, United States, 95356
Poway, California, United States, 92064
Colorado Springs, Colorado, United States, 80909
Lakewood, Colorado, United States, 80228
Waterford, Connecticut, United States, 06385
Coral Springs, Florida, United States, 33067
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32216
Orlando, Florida, United States, 32806
Oak Forest, Illinois, United States, 60452
Oak Park, Illinois, United States, 03440
Edina, Minnesota, United States, 55435
Saint Louis Park, Minnesota, United States, 55416
Jackson, Mississippi, United States, 39202
Teaneck, New Jersey, United States, 07666
Liverpool, New York, United States, 13088
Rochester, New York, United States, 14620
Asheville, North Carolina, United States, 28803
Hickory, North Carolina, United States, 28602
Winston-Salem, North Carolina, United States, 27103
Charleston, South Carolina, United States, 29414
Florence, South Carolina, United States, 29501
Ladson, South Carolina, United States, 29456
West Columbia, South Carolina, United States, 29169
Rapid City, South Dakota, United States, 57701
Germantown, Tennessee, United States, 38138
Abilene, Texas, United States, 79606
Arlington, Texas, United States, 76012
Austin, Texas, United States, 78705
Beaumont, Texas, United States, 77707
Bellaire, Texas, United States, 77401
Dallas, Texas, United States, 75231
Round Rock, Texas, United States, 78681
San Antonio, Texas, United States, 78251
The Woodlands, Texas, United States, 77384
Willow Park, Texas, United States, 79606
Salt Lake City, Utah, United States, 84107
Fairfax, Virginia, United States, 22031
Lynchburg, Virginia, United States, 24502
Bellevue, Washington, United States, 98004
Best of luck with your investments!
Holtec deal & potential NuScale fallout
https://www.reuters.com/business/energy/holtec-gets-152-bln-loan-us-restart-nuclear-power-plant-2024-03-27/
The company also plans to build what will be its first two small modular reactor (SMR) units at the site, which will not be part of the project that is eligible for the loan.
NuScale's SMR technology is the only one to have received design certification from the U.S. nuclear power regulator last year. But the company has faced cost and subscription issues and had to shelve one of its SMR projects.
Anticipate July 2025 approval; NuScale sees no perceived
challenges to achieving this timeline
BTIG: $50 Target Price
https://www.marketbeat.com/instant-alerts/nasdaq-otlk-upgrade-2024-03-27/
A number of analysts are starting to up their price targets. I spaced up for better legibility:
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) was upgraded by stock analysts at BTIG Research from a "neutral" rating to a "buy" rating in a research note issued on Wednesday, Marketbeat.com reports. The brokerage presently has a $50.00 price target on the stock. BTIG Research's price objective would suggest a potential upside of 476.04% from the company's current price.
OTLK has been the subject of a number of other research reports.
Ascendiant Capital Markets raised their price objective on Outlook Therapeutics from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, December 29th.
Capital One Financial reiterated an "overweight" rating on shares of Outlook Therapeutics in a research report on Friday, February 16th.
Guggenheim upgraded Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $40.00 target price for the company in a research report on Thursday, January 25th.
Brookline Capital Management upgraded Outlook Therapeutics from a "hold" rating to a "buy" rating and set a $31.40 target price for the company in a research report on Thursday, January 25th.
Finally, HC Wainwright boosted their price objective on Outlook Therapeutics to $30.00 and gave the company a "buy" rating in a research report on Monday.
One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company.
According to data from MarketBeat.com, Outlook Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.43.
now 38 recruiting sites!
Updated 2024-03-26. The sites:
Bakersfield, California, United States, 93309
Beverly Hills, California, United States, 90210
Huntington Beach, California, United States, 92647
Modesto, California, United States, 95356
Poway, California, United States, 92064
Colorado Springs, Colorado, United States, 80909
Lakewood, Colorado, United States, 80228
Waterford, Connecticut, United States, 06385
Coral Springs, Florida, United States, 33067
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32216
Orlando, Florida, United States, 32806
Oak Forest, Illinois, United States, 60452
Edina, Minnesota, United States, 55435
Saint Louis Park, Minnesota, United States, 55416
Jackson, Mississippi, United States, 39202
Liverpool, New York, United States, 13088
Asheville, North Carolina, United States, 28803
Hickory, North Carolina, United States, 28602
Winston-Salem, North Carolina, United States, 27103
Charleston, South Carolina, United States, 29414
Ladson, South Carolina, United States, 29456
West Columbia, South Carolina, United States, 29169
Rapid City, South Dakota, United States, 57701
Germantown, Tennessee, United States, 38138
Arlington, Texas, United States, 76012
Austin, Texas, United States, 78705
Beaumont, Texas, United States, 77707
Bellaire, Texas, United States, 77401
Dallas, Texas, United States, 75231
Round Rock, Texas, United States, 78681
San Antonio, Texas, United States, 78251
The Woodlands, Texas, United States, 77384
Salt Lake City, Utah, United States, 84107
Fairfax, Virginia, United States, 22031
Lynchburg, Virginia, United States, 24502
Bellevue, Washington, United States, 98004
Silverdale, Washington, United States, 98383
At this stage, a smidge over 10 patients by site would get OTLK to the target 400 patients. Plus a few more just in case.
The first sites were open for recruitment close to two months ago.
Best of luck with your investments!
Yes, end of May ! Thanks.
Bought another slide today, $8.06.
Best of luck with your investments!
.. 34 sites recruiting.
https://clinicaltrials.gov/study/NCT06190093#contacts-and-locations
Best of luck with your investments!
The next logical news would be approval in a couple of month, say end of June.
A decision from the European Commission is expected around 67 days after the CHMP opinion
Thanks! Link to the news on Nasdaq
https://www.nasdaq.com/articles/outlook-therapeutics-receives-positive-chmp-opinion-for-ons-5010-to-treat-wet-amd
Best of luck with your investments!
Now 31 sites recruiting.
Beverly Hills, California, United States, 90210
Modesto, California, United States, 95356
Poway, California, United States, 92064
Colorado Springs, Colorado, United States, 80909
Waterford, Connecticut, United States, 06385
Coral Springs, Florida, United States, 33067
Fort Lauderdale, Florida, United States, 33308
Jacksonville, Florida, United States, 32216
Orlando, Florida, United States, 32806
Edina, Minnesota, United States, 55435
Saint Louis Park, Minnesota, United States, 55416
Jackson, Mississippi, United States, 39202
Liverpool, New York, United States, 13088
Asheville, North Carolina, United States, 28803
Hickory, North Carolina, United States, 28602
Winston-Salem, North Carolina, United States, 27103
Charleston, South Carolina, United States, 29414
Ladson, South Carolina, United States, 29456
West Columbia, South Carolina, United States, 29169
Germantown, Tennessee, United States, 38138
Arlington, Texas, United States, 76012
Austin, Texas, United States, 78705
Bellaire, Texas, United States, 77401
Dallas, Texas, United States, 75231
Round Rock, Texas, United States, 78681
San Antonio, Texas, United States, 78251
The Woodlands, Texas, United States, 77384
Salt Lake City, Utah, United States, 84107
Fairfax, Virginia, United States, 22031
Lynchburg, Virginia, United States, 24502
Silverdale, Washington, United States, 98383
Best of luck with your investments!
With pre-commercial biotech, it's hard to know what's going on behind the scenes.
I went back to the Feb 2024 presentation, and if the EU/UK does approve in H1 as hoped by management (or later), that market looks like a great commercial opportunity:
Given today's PPS, it could be simply getting back to a baseline PPS (say around $10 post reverse split) or some 'rumor'. Anyways, I keep being hopeful for the medium term (6 month/2 years) for this investments.
Best of luck with your investments!
From the CC, a couple of snippets from John Hopkins.
One way to understand SMR:
We're very, you know, we're -- one thing we've done is a lot of monies with the $1.8 billion that's been invested in NuScale, a lot of that monies was de-risk in our module in actually scaling up and modeling to where a lot of it's off the shelf. And as we mentioned before, our fuel comes from traditional conventional fuel. Also from a supply chain, we continue to build out, but I was just with, this is John Hopkins, with the CEO of Doosan, as I mentioned during the script, that they made significant progress, anticipating the future of modules. Because as you know, our model is predicated not just to do a one-off project. These are fungible assets. We're going to build them in a factory and ship them.
And so right now, we're pretty confident we'll keep up to demand as it comes in. But we're also very cognizant, we're not going to overextend our capacity to execute, which is very key. So, with our strategic partners, and the beauty of these strategic partners in Japan and Korea and the U.S., not only the suppliers or OEMs, but they're also investors. So they're taking a holistic view, not looking at a one-off, which affords us very competitive rates from that, because the way we operate is that these suppliers recognize they have to be commercially viable. It's just not viable. They're just not given that work will come that way.
So I was just with the CEO of Doosan, my team. We're just out in Japan. And we stay in regular contact. And we continue to build our supply chain out both locally within the U.S. and international.
Well, let me just say, you know, this time last year when we talked it was all about coal refurbishment working with utilities and it quickly became more process oriented where industrials are looking at clean energy for process heat or hydrogen ammonia. And now there's the big push on energy consumption for data centers and AI. Where I think near-term we could come from is the project we mentioned in RoPower. I'm hopeful that in April, we've pretty much, Florida is the prime on this with the subcontractor. Florida is operated under a limited notice to proceed. We're in the final negotiations of our limited notice to proceed, as well as our technology licensing agreement. So the timeline right now hopefully is by early April, we'll be doing a signing ceremony to kick off this project.
So that one could be first out of the chute or again as I said before, I don't want to set an early expectation, but our project with Standard Power still continues to proceed. So, and then I will say I've never seen anything like it. This whole data center, AI, with some of the Tier 1 alphas in that industry, they need energy. And we're in discussions with not only Tier 1, but others. So it's a timing's everything, but we're just seeing the market continue to build.